Immunovant (IMVT) Stock Forecast, Price Target & Predictions
IMVT Stock Forecast
Immunovant stock forecast is as follows: an average price target of $42.83 (represents a 44.35% upside from IMVT’s last price of $29.67) and a rating consensus of 'Buy', based on 22 wall street analysts offering a 1-year stock forecast.
IMVT Price Target
The average price target for Immunovant (IMVT) is $42.83 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $57.00 to $5.00. This represents a potential 44.35% upside from IMVT's last price of $29.67.
IMVT Analyst Ratings
According to 22 Wall Street analysts, Immunovant's rating consensus is 'Buy'. The analyst rating breakdown for IMVT stock is 0 'Strong Buy' (0.00%), 15 'Buy' (68.18%), 5 'Hold' (22.73%), 2 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Immunovant Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Douglas Tsao | H.C. Wainwright | $51.00 | $30.20 | 68.87% | 71.89% |
| Jun 03, 2024 | Leland Gershell | Oppenheimer | $46.00 | $25.39 | 81.17% | 55.04% |
| May 30, 2024 | Yatin Suneja | Guggenheim | $48.00 | $26.41 | 81.75% | 61.78% |
| May 30, 2024 | Yasmeen Rahimi | Piper Sandler | $57.00 | $27.83 | 104.81% | 92.11% |
| Mar 13, 2024 | Corinne Johnson | Goldman Sachs | $50.00 | $31.82 | 57.13% | 68.52% |
| Sep 26, 2022 | Colin Bristow | UBS | $5.00 | $4.88 | 2.46% | -83.15% |
The latest Immunovant stock forecast, released on Sep 10, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $51.00, which represents a 68.87% increase from the stock price at the time of the forecast ($30.20), and a 71.89% increase from IMVT last price ($29.67).
Immunovant Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 5 |
| Avg Price Target | $51.00 | $51.00 | $50.40 |
| Last Closing Price | $29.67 | $29.67 | $29.67 |
| Upside/Downside | 71.89% | 71.89% | 69.87% |
In the current month, the average price target of Immunovant stock is $51.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 71.89% increase as opposed to Immunovant's last price of $29.67. This month's average price target is down 0.00% compared to last quarter, and up 1.19% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 09, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 31, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 30, 2024 | Guggenheim | Buy | Buy | Hold |
| May 30, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 29, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Dec 21, 2023 | Deutsche Bank | Buy | Buy | Hold |
| Oct 13, 2023 | UBS | Neutral | Buy | Upgrade |
Immunovant's last stock rating was published by Piper Sandler on Sep 12, 2024. The company gave IMVT a "Overweight" rating, the same as its previous rate.
Immunovant Financial Forecast
Immunovant Revenue Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Immunovant's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMVT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Immunovant EBITDA Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict IMVT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunovant's previous annual EBITDA (undefined) of $NaN.
Immunovant Net Income Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-107.62M | $-105.18M | $-99.68M | $-95.73M | $-91.16M | $-84.94M | $-86.21M | $-76.54M |
| High Forecast | $-107.62M | $-105.18M | $-99.68M | $-95.73M | $-91.16M | $-84.94M | $-76.47M | $-76.54M |
| Low Forecast | $-107.62M | $-105.18M | $-99.68M | $-95.73M | $-91.16M | $-84.94M | $-95.94M | $-76.54M |
| Surprise % | - | - | - | - | - | - | - | - |
Immunovant's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMVT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Immunovant SG&A Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Immunovant's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMVT last annual SG&A of $NaN (undefined).
Immunovant EPS Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.74 | $-0.72 | $-0.68 | $-0.66 | $-0.62 | $-0.58 | $-0.59 | $-0.52 |
| High Forecast | $-0.74 | $-0.72 | $-0.68 | $-0.66 | $-0.62 | $-0.58 | $-0.52 | $-0.52 |
| Low Forecast | $-0.74 | $-0.72 | $-0.68 | $-0.66 | $-0.62 | $-0.58 | $-0.66 | $-0.52 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Immunovant's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMVT previous annual EPS of $NaN (undefined).
Immunovant Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARQT | Arcutis Biotherapeutics | $10.66 | $31.00 | 190.81% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ETNB | 89bio | $8.48 | $22.00 | 159.43% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| ABUS | Arbutus Biopharma | $4.47 | $8.50 | 90.16% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| IMVT | Immunovant | $29.67 | $42.83 | 44.35% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
IMVT Forecast FAQ
Is Immunovant a good buy?
Yes, according to 22 Wall Street analysts, Immunovant (IMVT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 68.18% of IMVT's total ratings.
What is IMVT's price target?
Immunovant (IMVT) average price target is $42.83 with a range of $5 to $57, implying a 44.35% from its last price of $29.67. The data is based on 22 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Immunovant stock go up soon?
According to Wall Street analysts' prediction for IMVT stock, the company can go up by 44.35% (from the last price of $29.67 to the average price target of $42.83), up by 92.11% based on the highest stock price target, and down by -83.15% based on the lowest stock price target.
Can Immunovant stock reach $40?
IMVT's average twelve months analyst stock price target of $42.83 supports the claim that Immunovant can reach $40 in the near future.
What is Immunovant's current price target trend?
1 Wall Street analyst forecast a $51 price target for Immunovant (IMVT) this month, up 71.89% from its last price of $29.67. Compared to the last 3 and 12 months, the average price target increased by 71.89% and increased by 69.87%, respectively.
What are Immunovant's analysts' financial forecasts?
Immunovant's analysts financial forecasts for the fiscal year (Mar 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-339M (high $-329M, low $-349M), average SG&A $0 (high $0, low $0), and average EPS is $-2.32 (high $-2.253, low $-2.386). IMVT's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-408M (high $-408M, low $-408M), average SG&A $0 (high $0, low $0), and average EPS is $-2.794 (high $-2.794, low $-2.794).